비용-효과 분석 기법을 이용한 Gemcitabine 외래 항암 치료의경제성 평가 = Economic Evaluation of Gemcitabine-cisplatin Chemotherapy for Non Small-Cell Lung Cancer Patient in an Outpatient Setting

다국어 초록 (Multilingual Abstract)

This analysis was conducted to evaluate the cost-effectiveness of gemcitabine-cisplatin chemotherapy for non
small-cell lung cancer patients in an outpatient setting compared with the traditional inpatient setting. Methods: A cost-effective
analysis was conducted from a societal perspective. The effects of treatment, which was measured as an adverse event
rate, were abstracted from a published literature search and empirical data from one university hospital. The costs included
both direct and indirect costs. Direct costs included hospitalizations, outpatient visits, and lab tests. Pharmaceutical costs
were excluded in analysis because they were same for both options. Indirect costs included productivity loss of patients as
well as care-givers. In order to determine the robustness of the results, sensitivity analysis on treatment protocol was conducted.
Results: Literature search showed no difference in adverse effect rates between inpatient treatment protocol and
outpatient treatment protocol. Therefore, this analysis is a cost-minimization analysis. Cost-savings in the outpatient setting
was 555,936 won for one treatment cycle. Our sensitivity analysis indicated that the outpatient chemotherapy still
showed cost-savings, regardless of changes in treatment protocol. Conclusion: The outpatient gemcitabine-cisplatin chemotherapy
for non small-cell lung cancer resulted in cost savings compared to inpatient chemotherapy. More importantly,
outpatient chemotherapy could improve the utilization of health service resources in terms of available beds.

다국어 초록 (Multilingual Abstract)

This analysis was conducted to evaluate the cost-effectiveness of gemcitabine-cisplatin chemotherapy for non
small-cell lung cancer patients in an outpatient setting compared with the traditional inpatient setting. Methods: A cost-effective
analysis was conducted from a societal perspective. The effects of treatment, which was measured as an adverse event
rate, were abstracted from a published literature search and empirical data from one university hospital. The costs included
both direct and indirect costs. Direct costs included hospitalizations, outpatient visits, and lab tests. Pharmaceutical costs
were excluded in analysis because they were same for both options. Indirect costs included productivity loss of patients as
well as care-givers. In order to determine the robustness of the results, sensitivity analysis on treatment protocol was conducted.
Results: Literature search showed no difference in adverse effect rates between inpatient treatment protocol and
outpatient treatment protocol. Therefore, this analysis is a cost-minimization analysis. Cost-savings in the outpatient setting
was 555,936 won for one treatment cycle. Our sensitivity analysis indicated that the outpatient chemotherapy still
showed cost-savings, regardless of changes in treatment protocol. Conclusion: The outpatient gemcitabine-cisplatin chemotherapy
for non small-cell lung cancer resulted in cost savings compared to inpatient chemotherapy. More importantly,
outpatient chemotherapy could improve the utilization of health service resources in terms of available beds.

참고문헌 (Reference)

1 김성재, "가정전문간호사의 정체성-포커스 그룹 연구방법의 적용" 한국간호과학회 36 (36): 103-113, 2006

2 Holmes, S, "The oral complications of specific anti-cancer therapy" 28 : 343-360, 1991

3 Park,H.J., "The effects of mouth care with sterile normal saline on chemotherapy-induced stomatitis" 25 : 5-16, 1995

4 Anderson, H, "Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A Phase II study" 12 : 1821-1826, 1994

5 "Retrieved October 20"

6 Yang,B.M, "Health economics" Nanamsinseo 1999

7 Bischoff, H. G., "Experiences with gemcitabine in advanced non-small-cell lung cancer (NSCLC): Report of a phase - 1 dose - finding study of gemcitabine and ifosphamide" 6 : 89-, 1995

8 Rice,D, "Estimating the cost of illness" 57 : 424-440, 1967

9 Chang, H. J., "Efficacy of gemcitabine chemotherpy in advanced Non- Small-Cell Lung Cancer (NSCLC): A phase 2 study" 31 : 523-533, 1999

10 Abratt, R. P., "Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study" 12 : 1535-1540, 1994

11 Kim,S.K, "Cost of non-small-cell lung cancer, Dailymedi. Retrieved October 20, 2006"

12 Ministry of Health & Welfare, "Annual report of the Korea central cancer registry. Retrieved October 20"